Format

Send to

Choose Destination
MAbs. 2016 Jul;8(5):854-60. doi: 10.1080/19420862.2016.1168956. Epub 2016 Mar 30.

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.

Author information

1
a GeNeuro SA, Chemin des Aulx 18 , Plan-les-Ouates/Geneva , Switzerland.
2
b Division of Clinical Pharmacology and Toxicology, Rue Perret-Gentil, University of Geneva , Geneva , Switzerland.
3
c IPM Biotech GmbH , Lademannbogen 61, Hamburg , Germany.
4
d Department of Pharmacology , University of Pretoria , Pretoria , South Africa.

Abstract

GNbAC1 is a humanized IgG4 monoclonal antibody antagonist of Mulitple Sclerosis Retrovirus Envelope (MSRV-Env), a protein that could play a critical role in multiple sclerosis. This randomized placebo-controlled dose-escalation study evaluated the safety and pharmacokinetics of GNbAC1 in 21 healthy volunteers after single intravenous infusion at doses of 6, 18 and 36 mg/kg. Lumbar punctures were performed at days 2, 15 or 29 to measure GNbAC1 concentrations in cerebrospinal fluid (CSF). GNbAC1 was well tolerated. Serum data show a dose-linear pharmacokinetics. A mean CSF/serum ratio of 0.12% was observed at Day 2, increasing to 0.39% at Day 15 and 0.42% at Day 29. Linear regression analysis shows a relationship between GNbAC1 CSF/serum ratio and albumin CSF/serum ratio and a relationship at the limit of statistical significance with the timing of CSF sampling.

KEYWORDS:

Cerebrospinal fluid; clinical trial; monoclonal antibody; multiple sclerosis; pharmacokinetics; safety

PMID:
27030142
PMCID:
PMC4968100
DOI:
10.1080/19420862.2016.1168956
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center